Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03421353
Title AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

Therapies

AZD9150 + Cisplatin + Durvalumab + Gemcitabine

AZD9150 + Carboplatin + Durvalumab + Gemcitabine

AZD9150 + Cisplatin + Durvalumab + Fluorouracil

AZD9150 + Durvalumab

AZD9150 + Carboplatin + Durvalumab + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.